---
figid: PMC5515628__coaci-17-309-g002
figtitle: AD immunopathology and mechanisms of action of targeted therapies
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Danio rerio
- Homo sapiens
pmcid: PMC5515628
filename: coaci-17-309-g002.jpg
figlink: /pmc/articles/PMC5515628/figure/F1/
number: F1
caption: 'AD immunopathology and mechanisms of action of targeted therapies. AD immunopathology
  (central picture): damage in the skin barrier promotes the penetration of allergens
  into the skin and facilitate the entrance of microbial products. Antigens are taken
  up by LC and IDEC, initiating the sensitization and T-cell driven immune response.
  In the acute phase, Th2 and Th22 responses are augmented with contribution of Th17.
  The proinflammatory mediators produced in this phase further contribute to the impairment
  of the skin barrier and to the activation of different cell types that enhance the
  skin inflammation. Progression into chronicity involves an increased role of the
  Th1 pathway, but with important contributions of other T-cell subpopulations. Targeted
  therapies (external pictures, counter-clockwise from top left). Mechanism of action
  of nemolizumab (anti-IL-31 receptor antibody); omalizumab (anti-IgE antibody); JAK
  inhibitors; dupilumab (anti-IL-4/IL-13 receptors antibody); PDE4 inhibitors; and
  ustekinumab (anti-IL-12/-23p40 antibody). AD, atopic dermatitis; B, basophil; DC,
  dendritic cell; E, eosinophil. IDEC, inflammatory dendritic epidermal cells; ILC,
  innate lymphoid cell; LC, Langerhans cells; MC, mast cell; PDE, phosphodiesterase;
  Th, T-helper.'
papertitle: Atopic dermatitis phenotypes and the need for personalized medicine.
reftext: Beatriz Cabanillas, et al. Curr Opin Allergy Clin Immunol. 2017 Aug;17(4):309-315.
year: '2017'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9190658
figid_alias: PMC5515628__F1
figtype: Figure
redirect_from: /figures/PMC5515628__F1
ndex: 65d133a6-df09-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5515628__coaci-17-309-g002.html
  '@type': Dataset
  description: 'AD immunopathology and mechanisms of action of targeted therapies.
    AD immunopathology (central picture): damage in the skin barrier promotes the
    penetration of allergens into the skin and facilitate the entrance of microbial
    products. Antigens are taken up by LC and IDEC, initiating the sensitization and
    T-cell driven immune response. In the acute phase, Th2 and Th22 responses are
    augmented with contribution of Th17. The proinflammatory mediators produced in
    this phase further contribute to the impairment of the skin barrier and to the
    activation of different cell types that enhance the skin inflammation. Progression
    into chronicity involves an increased role of the Th1 pathway, but with important
    contributions of other T-cell subpopulations. Targeted therapies (external pictures,
    counter-clockwise from top left). Mechanism of action of nemolizumab (anti-IL-31
    receptor antibody); omalizumab (anti-IgE antibody); JAK inhibitors; dupilumab
    (anti-IL-4/IL-13 receptors antibody); PDE4 inhibitors; and ustekinumab (anti-IL-12/-23p40
    antibody). AD, atopic dermatitis; B, basophil; DC, dendritic cell; E, eosinophil.
    IDEC, inflammatory dendritic epidermal cells; ILC, innate lymphoid cell; LC, Langerhans
    cells; MC, mast cell; PDE, phosphodiesterase; Th, T-helper.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - caz
  - l(1)20Ca
  - sta
  - mip40
  - L12
  - Cpr11A
  - RpL12
  - l(1)L12
  - mc
  - dc
  - tht
  - dnc
  - RpL23
  - Amph
  - ATPsynbeta
  - Atpalpha
  - hop
  - bsk
  - nsg2
  - osmr
  - kita
  - ngfra
  - th2
  - ifnphi1
  - il4
  - il13
  - il22
  - IL31
  - IL12A
  - IL12B
  - IL37
  - IL23A
  - CDKN2A
  - CDKN2D
  - F9
  - REG1A
  - H3P13
  - IL9
  - RPSA
  - MAPK1
  - PSMD7
  - TP63
  - ARHGEF2
  - RABEPK
  - LANCL1
  - EBNA1BP2
  - BRMS1L
  - ARMH1
  - H3P28
  - OSMR
  - RPL12
  - RSL1D1
  - IGKV1-5
  - LGALS3
  - RPL31
  - PDE4A
  - PDE4B
  - PDE4C
  - PDE4D
  - IFNA1
  - APRT
  - MFAP1
  - IL4
  - IL13
  - IL5
  - ATP8A2
  - IL22
  - JAK1
  - JAK2
  - JAK3
  - TYK2
---
